MRI-TRUS融合活检与系统活检前列腺癌检出率随时间变化:学习曲线的证据
该研究基于2007至2016年美国国家癌症研究所前瞻性数据库,纳入1528例接受多参数MRI后融合活检与系统活检的患者,按活检时间分为三个队列。结果显示融合活检在初期学习阶段后,临床显著前列腺癌检出率显著高于系统活检,且低危癌检出率更低,软件平台更新后融合活检检出率进一步提高。
要点
- 融合活检在初期学习阶段后,临床显著前列腺癌检出率显著高于系统活检。
- 融合活检在同期检出低危前列腺癌的比例显著低于系统活检。
- 多因素调整后,融合活检临床显著癌检出率随队列顺序显著增加。
核心结论
- 过去9年间融合活检的准确性显著提高;经过早期学习阶段后,融合活检检出的临床显著癌比例高于系统活检,临床不显著癌比例低于系统活检;软件进步使临床显著癌检出进一步增加。
研究设计与样本
- 前瞻性维护数据库的回顾性分析,纳入2007年至2016年接受多参数MRI后融合活检和系统活检的患者1528例,按首次活检时间分为3个队列:队列1(2007年7月至2010年12月)230例,队列2(2011年1月至2013年5月)537例,队列3(2013年5月至2016年4月)761例。
主要发现
- 队列1中融合活检与系统活检的临床显著癌检出率无显著差异(24.8% vs 22.2%,P=0.377)。
- 队列2中融合活检临床显著癌检出率显著高于系统活检(31.5% vs 25.0%,P=0.001),低危癌检出率显著低于系统活检(14.5% vs 19.6%,P<0.001)。
- 队列3中融合活检临床显著癌检出率显著高于系统活检(36.4% vs 30.3%,P<0.001),低危癌检出率显著低于系统活检(12.6% vs 16.7%,P<0.001)。
- 多因素调整年龄、PSA、种族、临床分期和MRI可疑评分后,融合活检临床显著癌检出率在后续队列中增加(队列2:OR 2.23,P=0.043;队列3:OR 2.92,P=0.007)。
关键数值与推荐
- 临床显著癌定义为Gleason评分7(3+4)或更高。
- 三个队列中位年龄(四分位距)分别为61.0(±9.0)岁、62.0(±7.3)岁和64.0(±11.0)岁(P<0.001)。
临床怎么用
- 原文未据此给出推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: To determine the effect of urologist and radiologist learning curves and changes in MRI-TRUS fusion platform during 9 years of NCI's experience with multiparametric magnetic resonance imaging (mpMRI)/TRUS fusion biopsy. METHODS: A prospectively maintained database of patients undergoing mpMRI followed by fusion biopsy (Fbx) and systematic biopsy (Sbx) from 2007 to 2016 was reviewed. The patients were stratified based on the timing of first biopsy. Cohort 1 (7/2007-12/2010) accounted for learning curve. Cohort 2 (1/2011-5/2013) and cohort 3 (5/2013-4/2016) included patients biopsied prior to and after debut of a new software platform, respectively. Clinically significant (CS) disease was defined as Gleason 7 (3+4) or higher. McNemar's test compared cancer detection rates (CDRs) of Sbx and Fbx between time periods. RESULTS: 1528 patients were included in the study with 230, 537 and 761 patients included in three respective cohorts. Median age (interquartile range) was 61.0 (±9.0), 62.0 (±7.3), and 64.0 (±11.0) years in three cohorts, respectively (P<0.001). Fbx and Sbx had comparable CS CDR in cohort 1 (24.8 vs 22.2%, P=0.377). Fbx detected significantly more CS disease compared to Sbx in the following two periods (cohort 2: 31.5 vs 25.0%, P=0.001; cohort 3: 36.4 vs 30.3%, P<0.001) and detected significantly less low risk disease in the same period (cohort 2: 14.5 vs 19.6%, P<0.001; cohort 3: 12.6 vs 16.7%, P<0.001). Even after multivariate adjustment with age, PSA, race, clinical stage and MRI suspicion score, Fbx CS cancer detection increased in successive cohorts (cohort 2: OR 2.23, P=0.043; cohort 3: OR 2.92, P=0.007). CONCLUSIONS: In the past 9 years, there has been significant improvement in the accuracy of Fbx. Our results show that after an early learning period, Fbx detected higher rates of CS cancer and lower rates of clinically insignificant cancer than Sbx. Software advances allowed for even greater detection of CS disease.
引用
- Calio B, Sidana A, Sugano D, et al. Changes in prostate cancer detection rate of MRI-TRUS fusion vs systematic biopsy over time: evidence of a learning curve. Prostate Cancer Prostatic Dis. 2017. PMID: 28762373. doi:10.1038/pcan.2017.34
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。